
Vericel (VCEL) Stock Forecast & Price Target
Vericel (VCEL) Analyst Ratings
Bulls say
Vericel Corp's positive outlook is supported by anticipated growth in its MACI product, which is expected to achieve a compound annual growth rate (CAGR) in volume of approximately 14.8%, along with annual average selling price (ASP) increases of 300 to 500 basis points. The company is projected to realize a substantial revenue increase of approximately 21.2% year-over-year in FY26, driven by the conversion of biopsies to MACI and the expected expansion in market demand. Additionally, the fourth quarter is poised for a notable revenue step-up, with projected earnings of $84.8 million, representing a 26% increase quarter-over-quarter, reflecting the strengthening fundamentals of Vericel's business model.
Bears say
Vericel Corp faces a negative outlook primarily due to lowered revenue expectations for its MACI product in fiscal years 2026 and 2027, reflecting a potential decline of approximately 200 basis points. Additionally, there are significant risks associated with slower adoption rates of MACI and MACI Arthro, reduced sales in the burn care market, and challenges related to the expansion of the sales force. These factors, combined with potential misses in top-line performance, could drive the company’s stock towards historical low valuation points.
This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.
Vericel (VCEL) Analyst Forecast & Price Prediction
Start investing in Vericel (VCEL)
Order type
Buy in
Order amount
Est. shares
0 shares